| Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide GE Benoist, RJ Hendriks, PFA Mulders, WR Gerritsen, DM Somford, ... Clinical pharmacokinetics 55, 1369-1380, 2016 | 97 | 2016 |
| Drug–drug interaction potential in men treated with enzalutamide: mind the gap GE Benoist, IM van Oort, S Smeenk, A Javad, DM Somford, DM Burger, ... British journal of clinical pharmacology 84 (1), 122-129, 2018 | 55 | 2018 |
| Prognostic value of novel liquid biomarkers in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: a prospective observational study GE Benoist, IM van Oort, E Boerrigter, GW Verhaegh, O van Hooij, ... Clinical chemistry 66 (6), 842-851, 2020 | 28 | 2020 |
| Analytical challenges in quantifying abiraterone with LC–MS/MS in human plasma GE Benoist, E van der Meulen, FJE Lubberman, WR Gerritsen, TJ Smilde, ... Biomedical chromatography 31 (11), e3986, 2017 | 25 | 2017 |
| Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer SH Tolmeijer, E Boerrigter, T Sumiyoshi, EM Kwan, SWS Ng, M Annala, ... Clinical Cancer Research 29 (15), 2835-2844, 2023 | 12 | 2023 |
| Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical … GE Benoist, E van der Meulen, IM van Oort, JH Beumer, DM Somford, ... Therapeutic drug monitoring 40 (2), 222-229, 2018 | 12 | 2018 |
| The combination of enzalutamide and opioids: a painful pitfall GE Benoist, IM van Oort, DM Burger, BCP Koch, N Mehra, NP van Erp Eur Urol 75 (2), 351-352, 2019 | 10 | 2019 |
| Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line … E Boerrigter, GE Benoist, IM van Oort, GW Verhaegh, O van Hooij, ... Molecular oncology 15 (9), 2453-2465, 2021 | 9 | 2021 |
| A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics FJE Lubberman, GE Benoist, W Gerritsen, DM Burger, N Mehra, ... Cancer Chemotherapy and Pharmacology 84, 1179-1185, 2019 | 9 | 2019 |
| The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients GE Benoist, IM van Oort, DM Burger, N Mehra, NP van Erp Cancer chemotherapy and pharmacology 85, 753-760, 2020 | 6 | 2020 |
| The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer E Boerrigter, GE Benoist, JK Overbeek, R Donders, N Mehra, IM van Oort, ... British Journal of Clinical Pharmacology 88 (3), 1170-1178, 2022 | 5 | 2022 |
| RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer E Boerrigter, GE Benoist, IM van Oort, GW Verhaegh, AFJ de Haan, ... Cancers 13 (24), 6279, 2021 | 5 | 2021 |
| A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer GE Benoist, MJ van der Doelen, R Ter Heine, NP van Erp, N Mehra British Journal of Clinical Pharmacology 84 (5), 1064-1067, 2018 | 5 | 2018 |
| Concentration‐QT modelling in early clinical oncology settings: Simulation evaluation of performance G Cantet, A Berges, R O'Sullivan, S Cohen‐Rabbie, C Dota, V Dubois, ... British Journal of Clinical Pharmacology 88 (3), 1010-1019, 2022 | 4 | 2022 |
| Hormone therapy in prostate cancer; a pharmacotherapeutic challenge H Westdorp, GE Benoist, HJ Schers, PH Van Erp, WR Gerritsen, ... Nederlands tijdschrift voor geneeskunde 159, A9250-A9250, 2015 | 4 | 2015 |
| Enzalutamide reduces oxycodone exposure in men with prostate cancer SEH Detert Oude Weme, LMG Hulskotte, WL Vervenne, ALT Imholz, ... Clinical Pharmacokinetics 62 (7), 989-996, 2023 | 3 | 2023 |
| The effect of a reduced dose of enzalutamide on fatigue and cognition. J Overbeek, E Boerrigter, GE Benoist, DM Somford, P Hamberg, J Tol, ... Journal of Clinical Oncology 41 (16_suppl), 5051-5051, 2023 | 1 | 2023 |
| 1619P Assessment of the pharmacokinetic interaction of enzalutamide with oxycodone in men with prostate cancer: The ENZYME study SEHDO Weme, WL Vervenne, ALT Imholz, R Cremers, ... Annals of Oncology 33, S1282, 2022 | 1 | 2022 |
| Integrating pharmacokinetics and molecular biomarkers in advanced prostate cancer GE Benoist | 1 | 2019 |
| A rapid and sensitive LC–MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction … LMG Hulskotte, I Wilbrink‐Pijffers, MEL Arbouw, GE Benoist, ... Biomedical Chromatography, e5874, 2024 | | 2024 |
Diederik M. SomfordUrologist, Canisius Wilhelmina Hospital, Nijmegen (NL)Verified email at cwz.nl
